CAR-T therapy News — every source, one live feed
Track CAR-T therapy news in real time — Engineered immune cell treatments expanding beyond blood cancers. fllwup^ collects the latest CAR-T therapy headlines from every major source into one live feed — free, no account, no algorithm. Coverage aggregated from BBC, Reuters, AP, NYT, TechCrunch, Al Jazeera, and 200+ other outlets.
Latest CAR-T therapy headlines
- Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna — Fierce Biotech
- Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal — Reuters
- Pfizer leaps into ‘in vivo’ CAR-T with latest China deal — BioPharma Dive
- Updated: Pfizer gets into in vivo CAR-T with up to $2.6B Chinese biotech licensing deal — Endpoints News
- Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B — Seeking Alpha
- Verismo Therapeutics Licenses In Vivo CAR T Engineering Technology to Extend Its Novel Multi-Chain KIR-CAR Platform — PR Newswire
- China offers CAR-T for $40,000; Novartis and Biogen both strike deals — Endpoints News
- How Should CAR T and Bispecifics Be Sequenced in Multiple Myeloma? — CancerNetwork
- Liquid Biopsy Cell-Free RNA Markers Predict CAR T Response in Large B Cell Lymphoma — GenomeWeb
- How dormant cancer cells protect pancreatic tumours from CAR T therapy — Drug Target Review
Follow CAR-T therapy live on fllwup^ · Follow in any RSS reader — or browse all topics.
More Health & Medicine: browse the category. Compare: fllwup^ vs Flipboard · vs Feedly · vs Google News · vs Apple News.